(Reuters) - Swiss drugmaker Novartis is still seeking to buy out the minority shareholders of eyecare group Alcon with a lowball offer, now worth some $9.7 billion. Here are some key facts about the ...
ZURICH (Reuters) - Signals from Swiss drugmaker Novartis that it could unload its struggling Alcon eyecare business is the latest step in dismantling former leader Dan Vasella's vision of building a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results